EP Patent

EP1865958A2 — Pharmacokinetically improved compounds

Assigned to Surface Logix Inc · Expires 2007-12-19 · 18y expired

What this patent protects

The present invention relates to inhibitors of ROCKl and R0CK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that are useful for the treatment of disease.

USPTO Abstract

The present invention relates to inhibitors of ROCKl and R0CK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCKl and or R0CK2 that are useful for the treatment of disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP1865958A2
Jurisdiction
EP
Classification
—
Expires
2007-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Surface Logix Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.